Natus Medical rejects CeriBell's EEG patent infringement allegation

Natus Medical has denied allegations that its brain electroencephalography products infringe a CeriBell patent, according to a MassDevice report on the dispute. The denial sets up a contested intellectual property fight between two vendors with overlapping footprints in scalp EEG monitoring for hospital neurology and critical care units.

CeriBell, founded in 2014 and headquartered in Sunnyvale, California, has built its identity around an AI-assisted EEG analysis platform designed to flag suspected seizure activity in critically ill patients. The company's CeriBell AI software processes scalp EEG recordings and is marketed to intensive care units and continuous EEG monitoring services.

Natus Medical, based in Middleton, Wisconsin, is an established neurodiagnostics vendor whose product lines span routine scalp EEG systems, long-term monitoring equipment, and intracranial recording tools used in epilepsy surgery workups. The company was acquired by ArchiMed in 2022 in a transaction valued at approximately $1.2 billion.

MassDevice reported the denial but did not specify which CeriBell patent is at issue or the forum in which the dispute was filed. The summary did not disclose a public docket number, claim chart, or court venue, leaving the underlying intellectual property claim publicly opaque.

What does the dispute mean for EEG practice?

The case matters to clinical neurophysiology because both companies sell into the same reading rooms and continuous monitoring units. A successful patent claim could force Natus customers to re-evaluate purchasing plans, software updates, or service contracts for equipment already deployed in epilepsy monitoring units and ICUs.

CeriBell's commercial focus centers on algorithmic interpretation of scalp EEG traces, while Natus competes on hardware, electrodes, and integrated software. That pattern suggests the dispute may target algorithmic components, though the inference remains unconfirmed without the underlying complaint.

Continuous EEG monitoring in critical care has grown steadily since the 2015 American Heart Association guidelines recommended it for cardiac arrest survivors. That expansion has created a larger market for AI-assisted seizure detection tools, intensifying competition between hardware-led and software-led vendors.

What is at stake for hospital procurement?

Hospital neurophysiology departments and ICU EEG programs depend on a small number of vendors. A ruling against Natus could leave sites weighing CeriBell-integrated platforms against existing Natus hardware with third-party software. Both paths carry costs, training requirements, and validation work under clinical laboratory standards.

The dispute arrives as AI-assisted EEG interpretation moves from investigational use into routine clinical deployment. CeriBell received FDA 510(k) clearance for its adult seizure detection algorithm in 2023 and has pursued additional clearances for pediatric and neonatal populations. Natus has invested in its own automated event detection features inside its NicVue and NeuroWorks software environments.

Procurement officers at academic centers will likely track the case closely. Long-term EEG monitoring contracts often run three to seven years, and any forced migration mid-cycle would create clinical and financial disruption for epilepsy monitoring units.

What changes for clinicians today?

For practicing electroencephalographers, nothing changes immediately. The denial is a litigation position, not a court ruling, and clinical decisions should continue to follow existing American Clinical Neurophysiology Society standards and local institutional policy.

The companies have not disclosed whether settlement discussions are underway or whether the dispute will proceed to discovery. Patent infringement cases in the medical device sector typically run 18 to 36 months before trial, and many resolve through licensing agreements or covenant-not-to-sue arrangements.

Pricing of scalp EEG hardware and cloud-based analysis subscriptions could also become a downstream issue. If the dispute produces royalties or product exclusions, both vendors may adjust contract terms for new and renewing customers through 2026 and 2027.

Tom Whitfield covers clinical neurophysiology industry and policy for EEG Signal.